WEKO3
アイテム
Positron Emission Tomography/Computed Tomography before Treatment as a Predictor of 90Y-Ibritumomab Tiuxetan Response
http://hdl.handle.net/10087/12770
http://hdl.handle.net/10087/1277032c5c59e-d6f1-4b4a-9a1a-d09af4430863
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
68_151.pdf (459.4 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2019-12-03 | |||||
| タイトル | ||||||
| タイトル | Positron Emission Tomography/Computed Tomography before Treatment as a Predictor of 90Y-Ibritumomab Tiuxetan Response | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | non-Hodgkin lymphoma | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | radioimmunotherapy | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | 90Y-Ibritumomab tiuxetan | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | FDG-PET╱CT | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | response predictor | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
Yudistiro, Ryan
× Yudistiro, Ryan× Heryanto, Yusri Dwi× Kodaira, Sayaka× Higuchi, Tetsuya× Arisaka, Yukiko× Tokue, Azusa× Taketomi-Takahashi, Ayako× Tsukamoto, Norifumi× Yokohama, Akihiko× Handa, Hiroshi× Koiso, Hiromi× Ishizaki, Takuma× Tsushima, Yoshiko |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background and Aims: Radioimmunotherapy (RIT) appears as one of the most effective treatment options for patientswith relapsed or resistant non-Hodgkin’s lymphoma (NHL). Our aim was to evaluate the role of pre-RIT 18F-fluorodeoxyglucose-positron emission tomography╱computed tomography (FDG-PET╱CT) as an early predictor of 90Y-Ibritumomabtiuxetan treatment response. Methods: We included consecutive 20 patients with relapsed NHL (10 males; meanage, 58.5 ± 8.9 years old) who were treated with 90Y-Ibritumomab tiuxetan. FDG-PET╱CT was performed before andafter treatment. Semiquantitative parameters of all measurable FDG-avid lesions were measured and averaged. Ameasurable FDG-avid lesion was defined as a lesion that showed FDG uptake higher than liver with a diameter morethan 1 cm. Treatment response was determined by visual assessment based on a five-point score criteria from FDGPET╱CT after treatment. Results: Fourteen patients (70%) were classified as responders and the other six patients(30%) as non-responders. All semiquantitative parameters except for MTV demonstrated significantly lower values inthe responders compared with the non-responders (p＜0.05). Conclusions: Semiquantitative evaluation by SUVmax,SUVpeak, and TLG before treatment were useful as early predictors of 90Y-Ibritumomab tiuxetan treatment response. | |||||
| 書誌情報 |
The Kitakanto medical journal = 北関東医学 巻 68, 号 3, p. 151-156, 発行日 2018-08-01 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1343-2826 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AN10585677 | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| 出版者 | ||||||
| 出版者 | 北関東医学会 | |||||
| 資源タイプ | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Journal Article | |||||
| 更新日 | ||||||
| 日付 | 2019-12-04 | |||||
| 日付タイプ | Created | |||||
